




Prevalence of Hearing Loss in the United States, 2001-2008





Age-Related Hearing Loss (ARHL) Basic Questions


- What are the consequences of ARHL for older adults?
- What is the impact of treating ARHL on older adults?
- How can ARHL be effectively addressed in the community?





Age-Related Hearing Loss (ARHL) Basic Questions


- What are the consequences of ARHL for older adults?
- What is the impact of treating ARHL on older adults?
- How can ARHL be effectively addressed in the community?

























4

Barriers to Amplification


United States (Arch Int Med, 2012) 26.7M adults ≥ 50 years with hearing loss 3.8M use hearing aids <u>Overall rate of HA use: 14.2%</u>

England and Wales (NICE Report, 2000) 8.1M with hearing loss 1.4M use hearing aids <u>Overall rate of HA use: 17.3%</u>

Barriers to Amplification




Barriers to Amplification





Barriers to Amplification


Awareness of impact/public health importance




amplifiers? Audiologists? ENTs? Hearing aid dispensers? Mail order hearing aids? Costco?

Barriers to Amplification Cost/Affordability Awareness & Understanding Access to Services &Technology Fechnology Design & Utility

Barriers to Amplification





6

Regulation & Legislation

Presidents Council of Advisors on Science & Technology (Report Oct 2015) National Academies of Sciences, Engineering, & Medicine (Report June 2016) Food and Drug Administration Federal Trade Commission



Regulation & Legislation

Over the Counter Hearing Aid Act 2017* *FDA Reauthorization Act



Amplification



Amplification

Hearing Aids:

Kegulated by the FDA \$800 to \$3000 per device Minimal insurance benefit (no Medicare benefit) Accepted gold standard of care



Personal Sound Amplification Products: Unregulated by the FDA Cost \$30-300 per device E-commerce Tremendous recent advances



Reed et al., JAMA, 2017; Reed et al., Otology & Neurotology, 201

Amplification

Legislation is moving faster than the science

What evidence do we currently have?

PSAPs/OTC devices

Low cost devices tend to produce high EIN, THD, and limit amplification to low frequencies (Chan & Mcpherson, 2000, 2015)

Some devices in the mid-price range performed similar to hearing aids (Callaway & Punch, 2008)

Comparison of PSAPs and Hearing aids shows high end devices provided appropriate levels of amplification and directional benefit for mild to moderate hearing loss (Smith et al., 2016)

Callaway & Punch, 2008 AJA; Chan & Mcpherson, 2015 BioMed Res Intl; Smith et al., 2016, Hearing Review

PSAPs/OTC devices

Literature Review

No preference for environmental and music sounds between PSAP and hearing aid – though hearing aid was preferred for speech (Breitbart et al, 2014)

Evidence that cost does not necessarily drive outcomes (Cox et al. 2014)

Efficacious consumer selection OTC approach (Humes et al., 2017)

~1.5 million w/ hearing loss own PSAP or OTC device and of them, ~18% would have purchased traditional hearing aid without PSAP option and ~75% used PSAP for hearing loss (Kochkin, 2010)

Breitbart et al., 2014 Poster; Cox et al., 2014 Gerontology; Humes et al., 2017 AJA; Kochkin 2010, Hearing Journal

Electroacoustic Analysis of PSAPs

Initial Investigation


Electroacoustic exploration of PSAPs and OTC HAs 10 Devices: 9 in \$150-400 range, 1 was \$30

6 Devices: appropriate frequency range (200-6000+ Hz), Relatively Low EIN (<24), Low THD (<1%)

6 Devices: able to approx. NAL targets within 10 dB at 6+ targets

3 Devices: able to approx. NAL targets within 5 dB at 6+ targets

Reed et al., JAMA, 2017; Reed et al., Otology & Neurotology, 2017



Study Objective

Comparative analysis of PSAPs and a hearing aid on speech-in-noise performance among adults with mild-tomoderate hearing loss

Methods Study Population

aring loss

Inclusion:

Inclusion:	Exclusion:
Mild-to-moderate sensorineural hearing loss (PTA .5-4k 21-55 dB in the better	Unilateral/asymmetric he
ear)	Conductive hearing loss
Adult on set hearing loss	Hearing loss secondar
60-85 years of age	conditions
No cognitive impairment (MMSE \ge 24)	Prior hearing aid usage


Powered to N=42 for non-inferiority trial with type I error rate of 0.05 and 80% power (Williams Design)


Methods Device Selection

One mid-level technology hearing aid (\$1910 wholesale cost)

Four electroacoustically acceptable PSAPs from in-house analysis: SoundHawk, SoundWorld Solutions CS-50+, Etymotic Bean, Tweak Amplifier

One electroacoustically unacceptable PSAP from in-house analysis: MSA-30x $\,$





Outcomes

Primary:

Change in % correct from baseline unaided speech-in-noise scores to that in aided conditions

Secondary:


Ability to approximate NAL perscriptive targets

Subjective perception of devices

Reed et al., JAMA, 20

Resul	ts
Demographics	
Number of Participants	N=42 (14 Male, 28 Female)
Mean Age	71.6 years (SD 6.0) (61-83 years)
Mean Perceived Duration of Hearing Loss	4.9 years (0-55 years)
Mean MMSE	28.8 (25-30)
Mean PTA (.5-4k) Right	34.7 dB (21.25-52.5 dB)
Mean PTA (.5-4k) Left	36.1 dB (22.25-51.25 dB)
Percent Reported Noise Exposure Hx.	33.3% (14/42)
Percent Reported Perceived Tinnitus	52.4% (22/42)
Percent Reported Perceived Hearing Loss	88.0% (37/42)
	Reed et al., JAMA, 20

		Result	:S	
Table. Accuracy in Speech Unders to Moderate Hearing Loss ^a	standing in Noise F	From Unaided to Aided With PS	APs and a Hearing Aid Among 42	Older Adults With Mild
to Moderate Hearing Loss*				
	Cost, US \$ ^b	Mean Accuracy, % (95% CI)	Change From Unaided Hearing, Percentage Points (95% CI)	Difference Between PSAP and Hearing Aid Change, Percentage Points (95% CI)
Unaided hearing		76.5 (72.7 to 80.3)		NA
Oticon Nera 2 hearing aid ^c	1910.00	88.4 (84.5 to 92.4)	11.9 (9.8 to 14.0)	
PSAP				
Sound World Solutions CS50+	349.99	87.4 (83.5 to 91.4)	11.0 (8.8 to 13.1)	-1.0 (-2.7 to 0.8)
Soundhawk	349.99	86.7 (82.7 to 90.6)	10.2 (8.0 to 12.3)	-1.8 (-3.5 to 0)
Etymotic BEAN	299.99	84.1 (80.2 to 88.1)	7.7 (5.5 to 9.8)	-4.3 (-6.1 to -2.5)
Tweak Focus	269.99	81.4 (77.4 to 85.3)	4.9 (2.8 to 7.0)	-7.0 (-8.8 to -5.3)
MSA 30X Sound Amplifier	29.99	65.3 (60.1 to 70.4)	-11.2 (-15.2 to -7.3)	-23.1 (-26.9 to -19.4)
Abbreviations: NA, not applicable; PS	Ar, personarsound a	implineadorrproducts. 30id	tions caso+, soundnawk, etymotic	BEAN, Tweak Focus) and storefront
^a The pure-tone average was 500-40 right ear and 36.1 in the left ear.	000 Hz; the mean d	Janu	l (MSA 30X Sound Amplifier). All dev ary 2016 and April 2016.	
^b The cost of the hearing aid was the University Audiology Clinic. PSAPs			on Nera 2 is a US Food and Drug Adn reas all other devices are PSAPs.	ninistration-regulated hearing aid,
iama.com			JAMA	July 4, 2017 Volume 318, Numbe



		Res	ults		
Device ability to a	pproxima	te NAL targ	et within 5	dB 500-4000	Hz
Device	500 Hz	1000 Hz	2000 Hz	4000 Hz	Total Targets Met
Hearing Aid	12/12	12/12	12/12	9/12	45/48 (93.75%)
CS50	12/13	8/13	8/13	5/13	33/52 (63.46%)
Soundhawk	13/13	7/13	4/13	11/13	35/52 (67.31%)
Bean	10/13	8/13	7/13	3/13	28/52 (53.85%)
Tweak	13/13	10/13	10/13	3/13	36/52 (69.23%)
MSA 30X	1/13	4/13	4/13	0/13	09/52 (17.3%)

Subjective Q	uality of De			;		
	НА	CS-50+	SoundHawk	Bean	Tweak	MSA-30X
Mean	2.03	2.27	2.12	3.39	3.03	4.75
Contrast to HA (p-value)	N/A	0.28	0.69	<.001	<.01	<.001

Discussion

Analysis suggests in <u>ideal conditions</u> two higher-end PSAPs are not significantly different from a hearing aid in speech-in-noise sentence testing while less advanced products may actually degrade speech-in-noise results

Study limitations include : One-time snapshot, Unilateral fitting, Ideal conditions (clinical setting, clear signal, audiologist fit device), Advantage to directionally capable devices, may not be representative population, analysis of other factors not included


Reed et al., JAMA, 2017; Reed et al., Otology & Neurotology, 2017

Pilot Study 2 Objective

Comparative analysis of different fitting conditions of PSAPs on speech-in-noise performance among adults with mild-tomoderate hearing loss

Study 2: MethodsSame criteria and same speech-in-noise outcomeMutof-Box Fit
Notevice manipulationMaraned Fit
User free to manipulate with
Custer free to manipulate with
instructions and full access
to internetMaraned Fit
Custer free to manipulate with
Custer free to manipulate with
the structure manipulate with structure manipulate with structure manipulate with structure manip

		St	udy 2	2: Re	sults		
				PS	APs		
		5	SOUNDHAW	/K		CS 50+	
Participa nt	Unaided	Out-of-the- Box	Advanced User	Gold Standard	Out-of-the-Box	Advanced User	Gold Standard
	63	75	87	77	62	82	85
002	55	54	75	84	54	61	59
003	62	80	81	84	74	86	82
004	64	72	69	80	72	69	74
005	55	70	77	68	60	71	75
006	64	67	51	64	67	63	67
007	72	62	60	70	44	66	78
008	28	58	56	68	48	51	52
009	50	00	07	01	66	77	77
Mean	57.16	69.80	71.60	75.09	0.61	69.38	71.97
SD	12.50	11.12	10.51	7.00	10.12	10.70	10.00
						Greene-Oliv	ver, 2017, Towsor



Discussion

Preliminary analysis suggests in ideal conditions audiologist adjusted PSAPs are superior in speech-in-noise sentence recognition improvement when compared to out of the box and patient fit conditions

Study limitations include : One-time snapshot, Unilateral fitting, Ideal conditions (clinical setting, clear signal, audiologist fit device), Advantage to directionally capable devices, may not be representative population, analysis of other factors not included

PSAPs/OTC hearing care may represent transitory step in hearing healthcare that addresses situation specific needs, Reduce amplification gap, Reduce time to hearing aid adoption, and increase technologic innovation

More research needed – efficacy and effectiveness trials


Reed et al., JAMA, 2017; Reed et al., Otology & Neurotology, 2017


Implementation

Baltimore HEARS (ACCESS HEARS) in the community


Dementia Clinic


Counseling and fitting in the clinic
























	Notes, questions, concerns: This week there was trouble adjusting the values with real of the second of the second and the second secon
Week 1	The solution of the second of the second plan different waves of expression uplantes. People came into her yroom with different waves of expression themselves, she we u d heller that the device was too lead.
Week 2	Notes, questions, concerns: The "huh" stopped videt away. Her arking vegat a character has abried his partered, the great of conversion by anish productors. The paper are to adjust the braving device to make this of more constraints.
Week 3	Notes, questions, concerns: <u>She kenga telling har hidrorial</u> cleric source activistely. The asked one questions had smoother satences. Here policine was extended. There burre less "haveg-up"s.
Week 4	Notes, questions, concerns: Sile segred to be less latorestel jn latving by way and including restrictions the second party when late did hat get ber way.
Week 5	Notes, questions, concerns: Her willing uses to make devisions is strengers. Such deviations have made some sense. Note: The diversion is still there but it seems to take more at a back sea



Acknowledgements

Lab: Frank R. Lin, MD, PhD Adele Goman, PhD Joshua Betz, MS Sara Mamo, AuD, PhD Jennifer Deal, PhD

Towson University: Peggy Korczak, MS, PhD Nicole Polyak, AuD Toni Green-Oliver, BS Funding: NIH KL2 Eleanor Schwartz Foundation

No other financial disclosers to report

